4.7 Editorial Material

Trigeminal neuralgia and the merit of small clinical trials

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions

Linda Al-Hassany et al.

Summary: Migraine is the second most disabling disorder worldwide, and the pharmacology and clinical effects of CGRP-targeted drugs are not fully understood. Factors such as sex, body-mass index, age, and ethnic background may affect the pharmacokinetics of these treatments, particularly Gepants. Patient characteristics may play a more prominent role in the management of migraine as more is learned about CGRP-targeted therapies.

LANCET NEUROLOGY (2022)

Review Medicine, General & Internal

Trigeminal Neuralgia

Giorgio Cruccu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Clinical Neurology

European Academy of Neurology guideline on trigeminal neuralgia

L. Bendtsen et al.

EUROPEAN JOURNAL OF NEUROLOGY (2019)

Review Clinical Neurology

CGRP as the target of new migraine therapies - successful translation from bench to clinic

Lars Edvinsson et al.

NATURE REVIEWS NEUROLOGY (2018)

Article Clinical Neurology

Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia

Zhen-long Qin et al.

CLINICAL NEUROLOGY AND NEUROSURGERY (2016)

Article Clinical Neurology

Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

Nanna B. Finnerup et al.

LANCET NEUROLOGY (2015)

Article Psychiatry

Is bigger better for depression trials?

Kenneth S. Liu et al.

JOURNAL OF PSYCHIATRIC RESEARCH (2008)